The Availability of Human Biospecimens to Support Biomarker Research

Tamsin E. Tarling1,2, Jennifer A. Byrne3,4 and Peter H. Watson1,2

1Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer, Victoria, BC, Canada. 2Canadian Tissue Repository Network, Vancouver, Canada. 3New South Wales Health Statewide Biobank, New South Wales Health Pathology, Camperdown, NSW, Australia. 4School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.

ABSTRACT: Preserved biospecimens held in biobank inventories and clinical archives are important resources for biomarker research. Recent advances in technologies have led to an increase in use of clinical archives in particular, in order to study retrospective cohorts and to generate data relevant to tissue biomarkers. This raises the question of whether the current sizes of biobank inventories are appropriate to meet the demands of biomarker research. This commentary discusses this question by considering data concerning overall biobank and biospecimen numbers to estimate current biospecimen supply and use. The data suggests that biospecimen supply exceeds current demand. Therefore, it may be important for individual biobanks to reassess the targets for their inventories, consider culling unused portions of these inventories, and shift resources towards providing prospective custom biobanking services.

KEYWORDS: Biobanks, Inventory, Utilization

RECEIVED: February 2, 2021. ACCEPTED: March 15, 2022.
TYPE: Review
FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
CORRESPONDING AUTHOR: Watson PH, Biobanking and Biospecimen Research Services, Deeley Research Centre, BC Cancer Victoria Center, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada. Email: pwatson@bccancer.bc.ca.

Introduction
Biomarker discovery, translation and validation in health research all depend on different types of biospecimen resources that enable the generation of data that are considered to provide distinct levels of evidence.1,2 In general terms, biomarker discovery depends on availability of relevant biospecimens in flexible formats appropriate for interrogation using a range of assays; biomarker translation depends on availability of biospecimens and data in the context of retrospective cohorts selected to be representative of specific clinical situations; and biomarker validation depends on availability of prospective patient cohorts assembled under specified criteria with associated biospecimens and outcomes data.3

Retrospective biospecimen cohorts necessary for biomarker discovery and translation mostly come either from research collections (ie, inventories of the many types of research biobank4,5) or from clinical archives.6 The biospecimens are typically tissue or blood samples that are mostly preserved in either a frozen format (tissue and blood in biobank inventories7) or a fixed format (formalin fixed and paraffin embedded tissues in clinical pathology archives8). However, the preferred source of retrospective tissue biospecimen cohorts has changed. Frozen format tissue biospecimens were essential for many of the research assays deployed in the 1980’s and 1990’s, and this provided the motivation for the development of biobanks in health research, with their extensive inventories.9 Since then the development of several high throughput technologies, combined with both analytical and bioinformatic approaches, have increased overall demand for all biospecimens.10,11 This has provided a stimulus for increased access to fixed tissues in clinical archives for retrospective studies.12,13 At the same time, there has been a recent increased demand for prospectively collected fresh tissue and blood samples,14,15 possibly attributable to the increased interest in the function of the immune system in health research. Collectively these trends have led to diminished demand for frozen biospecimens in biobank inventories (Figure 1). So, while there is continued increase in demand for biospecimens for biomarker research across the spectrum from discovery to validation, the changes in demand for the types of biospecimens in biobank inventories means that we should ask the question, "are there enough, too few, or too many biospecimens in research biobank inventories to support biomarker research demand." If there are too few of the right types of biospecimens, we should recognize this and consider how to rectify the situation. If there are too many, then it is possible that resources could be freed up from maintaining excessive collections.

This commentary will address this overall question through consideration of a series of preliminary questions that need to be examined to allow us to estimate supply and demand of biospecimens.

Biospecimen Supply and Demand
Definitions and limitations
Before diving into these questions around biobanks and their biospecimens, it is important to define the units of measure. The National Cancer Institute Best Practices for Biospecimen Resources defines human biospecimen resources as encompassing all types of specimen collections and data for research.

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
purposes and includes the facilities, policies and procedures inherent to biobanking operations. Consistent with this definition, a human health research biobank is considered here broadly as an entity that comprises a collection of biospecimens and data created in the course of a research project, study, or trial. Using this definition there are many types of biobank, but we will limit the focus here to academic biobanks, both small and large, with ‘classic’ operating models and inventories of biospecimens supporting academic health research. Biospecimens and associated data are the main products of these academic biobanks. The biospecimens are obtained from a donor and the data is either derived from the donor, from the management of the biobanking process, and/or from the data generated from analysis of biospecimens. We will also focus mostly on biobanks storing intact biospecimens as opposed to collections of nucleic acids derived from processing biospecimens. However, there are many types of biospecimens that can range from whole organs to small tissue blocks or thin sections of tissue or small volumes of fluids or fractions of these fluids, and many layers of granularity to the associated data. No consistent terminology or approach to denote size or volume of biospecimens (or extent of data) has been widely adopted in health research, as reflected in the several alternative terms (including; specimens, tissues, samples, blocks or aliquots) commonly used to indicate biospecimens. Therefore, we acknowledge that there are challenges in defining the numbers of biospecimens in a biobank and comparing these between different biobank inventories based on this lack of consistent terminology. However there are some relatively common and widely used approaches to processing some types of tissues (eg, cancer biospecimens) and fluids (eg, blood samples) that creates some consistency and supports comparisons. These processing approaches lead to the creation of relatively standard sizes of biospecimens for storage (eg, frozen tissues in 1.5 ml cryovials and frozen blood plasma and serum fractions in 500 ul-2 ml volumes) that are usually the basis of reported overall numbers of biospecimen units reported by biobanks. There are also similar challenges in making comparisons of numbers of biospecimens used for research. Publications listed in large online databases (eg, PubMed) provide the best data source to determine biospecimen use in research. However no standard terminology is used to indicate use of human biospecimens in papers, and no commonly defined data elements have been widely adopted to indicate the source, size or volume of biospecimens used. Furthermore, not all biospecimens used in research generate data that is reported in publications. However a reasonable estimate of the numbers, patterns and trends in biospecimen use in publications can be obtained by careful review of papers using defined search criteria.

**Biobank inventories**

There is no mandated requirement to register all forms of biobanks or their biospecimen collections in any country. This makes biobanks hard to find. Therefore in the past, attempts have been made to survey multiple data sources to identify
There are many types of online locators but some have defined online biobank locators to address some of these questions.\(^3\) We have taken the opportunity presented by several mature biobanks,\(^3,4\) and represent biobanks supporting a range of health research.\(^3,4\) The disease focused biobanks comprised either blood\(^37\) or tissue collections\(^38\) to support cancer research, and cardiovascular tissue\(^39\) and lung tissue\(^40\) collections that support health research in these respective areas. Details of the current number of biospecimens reported by each biobank are shown in Table 1, along with a calculated average of the estimated number of biospecimens per million population in British Columbia. This calculation also incorporates an estimate of the number of biospecimens held in small-medium sized biobanks, using the midpoint of the range of the estimated number of these other biobanks. This analysis, which estimates an average number of ~164 000 biospecimens stored in biobank inventories per million population, is based on data from only 1 province. However the total annual investment in health research in British Columbia is very close to the national average on a per capita basis ($13 vs $12 per person over the 4 year period 2008-2012) across all regions of Canada.\(^4\) It is therefore reasonable to assume that the average number of ~164 000 biospecimens stored in biobank inventories per million population is applicable to Canada and other countries with a comparable GDP and health research enterprise.

### Biobank inventory utilization

Current demand for biospecimens and utilization can best be deduced from an analysis of biospecimen use in published literature. We have previously conducted several different studies to assess trends in biospecimen use in health research over the past couple of decades.\(^10,42,43\) Most of these studies were concentrated on cancer research and looked at utilization from the viewpoint of selected individual research labs, research funders

| BIOBANKS\(^a\) | PURPOSE\(^a\) | # CASES | # BIOSPECIMENS | # BIOBANKS/M\(^b\) | # BIOSPECIMENS /M\(^c\) |
|----------------|----------------|---------|----------------|------------------|------------------|
| BC examples    | BC Generations | multipurpose | 30 000 | 122 000 | – | – |
| CVTR           | cardiovascular | 15 000 | 100 000 | – | – |
| Predict        | cancer | 13 000 | 79 000 | – | – |
| TTR            | cancer | 6400 | 46 000 | – | – |
| JHLTR          | lung | 3000 | 40 000 | – | – |
| BC averages\(^d\) | Large | – | 13 000 | 77 000 | 2 | 154,000 |
| Small-Medium   | – | 200 | 500 | 20 | 10,000 |
| All biobanks   | – | 13 200 | 77 500 | 22 | 164,000 |

\(^a\)Selected biobank examples, and the purpose with respect to the area of health research supported, are as follows: BC Generations = BC Generations cohort biobank (https://www.bcgenerationsproject.ca), CVTR = Cardiovascular Tissue Registry (https://www.hli.ubc.ca/our-services/cardiovascular-tissue-registry), PREDICT = Victoria Cancer Center blood biobank (http://www.bccancer.bc.ca/our-research/research-focus/engaging-patients-in-research), TTR = Tumour Tissue Repository (https://www.bcncr.ca/services/biobanking-biospecimen-research-services-bbrrs), JHLTR = James Hogg Lung Tissue Registry (https://www.hli.ubc.ca/our-services/lung-tissue-registry).

\(^b\)Large biobanks, \(\geq 1000\) biospecimens; Small-Medium biobanks \(<1000\) biospecimens.\(^3\)

\(^c\)# biobanks/M, number of biobanks per million population based on the current population of British Columbia (https://www2.gov.bc.ca/gov/content/data/statistics)

\(^d\)# biospecimens/M, number of biospecimens per million population based on the average numbers of biospecimens in the examples of biobanks in British Columbia.
and journals. However our most recent study in this area was directed more broadly to publications across all health research using a randomly selected cohort of 225 papers published over 2 decades from 2000 to 2020. While the primary focus was on the assessment of the trends in the complexity of biospecimens and their associated data used in health research, the study also generated data on the sources and numbers of these biospecimens used. In 2020, the most recent period analysed, the average numbers of total biospecimens used in each paper was 204 and 1/5 of collection pathways for biospecimen cohorts involved biobanks, and 14% overall were retrospective cohorts (ie, most likely drawn from frozen biospecimens in biobank inventories). The other 4% of cohorts involving biobanks were prospective cohorts (ie, most likely fresh biospecimens collected for the study by a biobank).

In order to express biospecimen utilization in the same terms as our estimate of supply, it is necessary to calculate the numbers of researchers per million population and their publication output. We will again draw on estimates for the number of health researchers in Canada and their typical annual output of publications utilizing biospecimens. The Canadian Institutes for Health Research has estimated in 2018 that there are 13 000 researchers from all pillars of health research in Canada. This translates into ~350 health researchers per million population in Canada. The typical annual output of publications utilizing biospecimens from these researchers can be estimated at 1.2 papers per researcher per year. This output estimate is based on a small but nationally representative group of cancer researchers assessed in a previous study of the publication output of Canadian cancer researchers funded by a national cancer research agency in 2011.

An estimate for current utilization rates from biobank inventories (demand) in Canada can be summarized in terms of total biospecimens used per year in retrospective cohorts drawn from biobanks and reported in publications by researchers. This estimate is calculated as follows: 204 biospecimens per average paper × 14% of biospecimen cohorts used are retrospective and from biobanks × 1.2 papers using biospecimens are generated by a researcher per year × 350 researchers per million population = ~12,000 biospecimens per million population.

The current overall balance sheet for supply versus demand for biobank inventories in Canada is therefore approximately 164 000 biospecimens per million population stored in biobank inventories versus 12 000 biospecimens per million population used per year for research, which equates to a ratio of 13:1.

Uncertainties and Projections

As already noted, there are several uncertainties on both sides of the balance sheet that could change these estimates of supply and demand. There are also several factors that might influence the balance in the future.

These initial estimates are based on extrapolation from relatively limited datasets within a few small studies. The limitations are in terms of accurate biobank numbers, definitions underlying reported numbers of biospecimens, estimates of average sizes of inventories and details restricting the extent of analysis of utilization of biospecimens to research papers across all areas of published health research.

The estimate of current supply at ~160 000 biospecimens stored/million population in Canada is lower than the estimates previously suggested for the US in 2000 and 2012 but is very comparable to the projections based on more recent data from Europe (Table 2). However the US estimates included processed derivatives such as nucleic acids as well as intact biospecimens and the European estimate may be conservative, as many small-medium sized biobanks are not represented in the directory. Differences in the scale of the health research enterprise, as reflected by overall GDP per person (USD) in each region (European Union 34, Canada 44, USA 64) may also influence these numbers.

The estimate of current demand at ~12 000 biospecimens used each year per million population may be influenced by the density of health researchers in Canada and the specific sector of health research under consideration. For example, cancer research has been at the forefront of health research in terms of discovery and translation of biomarkers into practice and may have higher demands for biospecimens. In addition, in many cases, biospecimen use reported within papers may not reflect all the biospecimens used in the research laboratory, for example in preliminary assay development and validation steps or in generating unpublished data. Biospecimen use in research supported by industry is also probably under-represented in the published literature. Perhaps more importantly, the number of biospecimens used to support any given study may relate to only a very small fraction of the individual biospecimen or aliquots of this biospecimen stored within a biobank inventory. Each biospecimen is often subdivided and stored as several blocks or aliquots and only fractions of these blocks and aliquots (eg, limited numbers of thin tissue sections from tissue blocks or small portions of fluid aliquots) may be used from a biobank for each study. Also, as illustrated in Table 1, large biobanks may hold many biospecimens per case.

Many factors may change these current estimates in the future. Our previous studies, focused on cancer research papers alone, have consistently identified a relatively steady proportion (~40% of all publications) that utilize biospecimens to generate at least some of the data reported. However we have also observed continuing trends towards increased biospecimen cohort sizes used in individual papers, which would be expected to continue to increase the scale of annual demand for biospecimens. Furthermore we have also seen changes in the dominant preferences in preservation formats for tissues, most recently from frozen format to FFPE tissue format, which would be expected to have an opposing effect and to reduce some demand for frozen tissue from biobank inventories.
mostly to frozen tissue and blood biospecimens. This is partly
to allow for case selection. Time and inventories need to be larger than the forecasted
to be maintained without exhausting biospecimens for some
defined section criteria. Therefore inventories, by design, need
and associated biospecimens from the collection that meet
questions will require selection of specific subsets of patients
of intended use it is anticipated that specific research
storage for many years before intended use occurs. At the
utilization indicates an oversupply. But as delineated in a recent
has surfaced in the past and the conclusion was drawn that low
debate will be offered here.

The question of underutilization of some biobank inventories
has surfaced in the past and the conclusion was drawn that low
utilization indicates an oversupply. But as delineated in a recent
set of papers, while individual biobank utilization rates are
very variable, these rates are also hard to judge as good or poor,
because they are affected by many factors. Nevertheless
when biobanks with similar designs and operational models are
compared, low utilization rates can be an indicator of performance.
In these cases, low utilization may arise because of low
visibility of the biobank for researchers, or restricted biobank
access policies, or just poor and/or obsolescent planning.

However low utilization can also reflect the maturity of the
biobank. Much of the value in utilizing retrospective cohorts of
biospecimens lies in the ability to link research findings with
clinical outcomes data (eg, data related to the response of the
donor to treatment). In cancer research the operational design
they contain biospecimens or associated data that are no longer
may experience reduced demand for their inventories because
of many ‘classic tumour biobanks’ involves collection and then
storage for many years before intended use occurs. At the
time of intended use it is anticipated that specific research
questions will require selection of specific subsets of patients
and associated biospecimens from the collection that meet
defined section criteria. Therefore inventories, by design, need
to be maintained without exhausting biospecimens for some
time and inventories need to be larger than the forecasted
demand to allow for case selection.

Many of the inventories that we have referred to here relate
mostly to frozen tissue and blood biospecimens. This is partly
related to the drivers for creating research biobanks to meet
demand specifically for this format of biospecimen. However
more recently we and others have reported a significant shift in
demand in favour of fresh and fixed biospecimens, espe-
cially those obtained from clinical archives, and also in favour
of reuse of ‘digital biospecimen data’. For example the use of
expression profile data available from online data repositories
to explore relationships between gene expression and patient
outcomes or images downloaded for analysis by artificial
intelligence approaches does not require analysis of new bio-
specimens. These shifts in demand serve to reduce the need
for large inventories and new biobank collections.

Many current biobanks face significant sustainability chal-
lenges. Many inventories are dominated by frozen format
biospecimens when relative demand for this format is decline-
ing as noted above. The relevance of these inventories is also
decreasing because their collections of biospecimens extend back
several decades to when treatment approaches for the associated
health conditions were often different. Furthermore priorities
across health research have also been changed by the COVID-
19 pandemic. We have previously highlighted the issue of
changing demand for simple quality biospecimens, that make
up much of the current inventories of tumour biobanks, versus
complex quality biospecimens. Hence many older biobanks
may experience reduced demand for their inventories because
they contain biospecimens or associated data that are no longer
required by contemporary research.

### Debating the balance sheet

Does a ratio of 13:1 for stored versus used biospecimens repre-
sent too much supply or too little demand, or both? In other
words, are there too many biospecimens that are never selected
for retrospective biomarker studies held in biobank inventories,
or are too few biospecimens applied for or made available by
restricted access biobanks? This question and the many factors
that might impact the conclusion, remain to be debated by all
stakeholders. However, some initial comments to ground this
debate will be offered here.

The question of underutilization of some biobank inventories
has surfaced in the past and the conclusion was drawn that low
utilization indicates an oversupply. But as delineated in a recent
set of papers, while individual biobank utilization rates are
very variable, these rates are also hard to judge as good or poor,
because they are affected by many factors. Nevertheless
when biobanks with similar designs and operational models are
compared, low utilization rates can be an indicator of performance.
In these cases, low utilization may arise because of low
visibility of the biobank for researchers, or restricted biobank
access policies, or just poor and/or obsolescent planning.

However low utilization can also reflect the maturity of the
biobank. Much of the value in utilizing retrospective cohorts of
biospecimens lies in the ability to link research findings with
clinical outcomes data (eg, data related to the response of the
donor to treatment). In cancer research the operational design
they contain biospecimens or associated data that are no longer
may experience reduced demand for their inventories because
of many ‘classic tumour biobanks’ involves collection and then
storage for many years before intended use occurs. At the
time of intended use it is anticipated that specific research
questions will require selection of specific subsets of patients
and associated biospecimens from the collection that meet
defined section criteria. Therefore inventories, by design, need
to be maintained without exhausting biospecimens for some
time and inventories need to be larger than the forecasted
demand to allow for case selection.

Many of the inventories that we have referred to here relate
mostly to frozen tissue and blood biospecimens. This is partly
related to the drivers for creating research biobanks to meet
demand specifically for this format of biospecimen. However
more recently we and others have reported a significant shift in
demand in favour of fresh and fixed biospecimens, espe-
cially those obtained from clinical archives, and also in favour
of reuse of ‘digital biospecimen data’. For example the use of
expression profile data available from online data repositories
to explore relationships between gene expression and patient
outcomes or images downloaded for analysis by artificial
intelligence approaches does not require analysis of new bio-
specimens. These shifts in demand serve to reduce the need
for large inventories and new biobank collections.

Many current biobanks face significant sustainability chal-
lenges. Many inventories are dominated by frozen format
biospecimens when relative demand for this format is decline-
ing as noted above. The relevance of these inventories is also
decreasing because their collections of biospecimens extend back
several decades to when treatment approaches for the associated
health conditions were often different. Furthermore priorities
across health research have also been changed by the COVID-
19 pandemic. We have previously highlighted the issue of
changing demand for simple quality biospecimens, that make
up much of the current inventories of tumour biobanks, versus
complex quality biospecimens. Hence many older biobanks
may experience reduced demand for their inventories because
they contain biospecimens or associated data that are no longer
required by contemporary research.

### Table 2. Estimates of the total number of specimens stored in research biobank inventories in different countries and regions. The estimates for the United States of America and the European Union are derived from the sources listed and for Canada is extrapolated from data from British Columba (see table 1).

| SOURCE      | COUNTRY/REGION | YEAR | # OF SPECIMENS | POPULATION | # SPECIMENS/M |
|-------------|----------------|------|----------------|------------|---------------|
| Eiseman50   | USA            | 2000 | 120M           | 285M       | 421,000       |
| Henderson29 | USA            | 2012 | 210M           | 314M       | 669,000       |
| Holub45     | EU             | 2016 | 60M            | 445M       | 135,000       |
| Canada      |                | 2020 | 6M             | 38M        | 164,000       |

*USA = United States of America; EU = European Union

*Year in which the study or survey or estimate was conducted.

*Number of specimens in millions (M); Note that USA and EU estimates include extracted biological derivative specimens such as nucleic acids as well as biospecimens.

*Number of specimens per million population

### Addressing the Balance Sheet

Given the preliminary conclusion that current supply in bio-
specimen inventories is well in excess of recent and projected
demand, the issue of reducing the scale of inventories needs to
be considered. As biobanks mature it is not unusual for them
to need to discard some biospecimens in order to free up storage
space or staff or financial resources dedicated to maintaining
the biobank inventory. This can become necessary in order to
take on new priorities and new biospecimens, as our analysis
above suggests. It can also become necessary because of major legacy events, such as reduced funding or limits to storage resources or biobank closure. Nevertheless it is challenging to determine the best approach to rationalizing and culling biobank inventories.69 Figure 2 summarizes the 4 main aspects to the decision process to keep or discard collections of biospecimens, and for many collections all aspects will be important to consider. Many classic operating model disease focused biobanks collect biospecimens using quality processes from generous patients. There is then an expectation from these donors that their donation will contribute to better treatment for others with the same disease.70 There is also an expectation from the biobank that the value of each biospecimen will increase as outcomes data matures and that such biospecimens will eventually be used in valuable research. This is particularly applicable to biospecimens that are judged to be rare and difficult to collect. However health research has finite resources and evolving priorities, and research needs change.71-73 as has also recently been demonstrated by the COVID-19 pandemic. Therefore, biobanks should regularly consider the value of the biospecimens in their inventories to prioritize portions of the inventory or the entire collection and accept that this evaluation becomes necessary with a major legacy event. In these circumstances biobanks should be prepared to discard low priority/high storage cost biospecimens in order to free up storage space and resources for higher priority/lower storage cost biospecimens.

**Conclusions**

This paper sets out to explore the issue of supply and demand for preserved biospecimens stored in academic health research biobanks that support biomarker research. It is based on relatively limited data available, but the estimates reached are consistent with the authors’ personal experiences and observations in health research and with other sources that have addressed related questions. Although the precision of the numbers can be questioned and the deductions debated, the data clearly points to the conclusion that biospecimen supply exceeds current demand. Therefore, it may be important for individual biobanks to reassess the targets for their inventories and shift resources towards providing prospective custom biobanking services. In addition, where space and fiscal resources become restrictive, consideration of culling portions of inventories should also be considered.

**Acknowledgements**

P.W. gratefully acknowledges support for this work by the Biobanking and Biospecimen Research Services Program at BC Cancer (supported by the Provincial Health Services Authority), the Canadian Tissue Repository Network (funded by grants from the Institute of Cancer Research, Canadian Institutes of Health Research and the Terry Fox Research Institute, and from the Canadian Cancer Research Alliance). J.A.B. gratefully acknowledges previous grant support from the Cancer Institute NSW Biobanking Stakeholder Network.
the NSW Biobank Certification Program (Grant ID’s 15/BIO/1-03 and 2017/BIO002) and support from the NSW Office of Health and Medical Research of the NSW Health Statewide Biobank.

Author Contributions
TT, JB and PW all equally contributed to the discussion that led to the generation of this manuscript. TT is the primary author. All authors have reviewed and discussed the results and contributed to the final manuscript.

Research Ethics Statement
No direct participation of human subjects was involved in this study and Research ethics board (REB/IRB) approval and informed consent are not required for this review.

ORCID iDs
Jennifer A. Byrne https://orcid.org/0000-0002-8923-0587
Peter H. Watson https://orcid.org/0000-0002-1642-0638

REFERENCES
1. Hayes DF. Biomarker validation and testing. Mol Oncol. 2015;9:960-966.
2. Simon RM, Puik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-1452.
3. Rush A, Matzke L, Cooper S, Greley C, Byrne JA, Watson PH. Research perspective on utilizing and valuing tumor biobanks. Biopreserv Biobank. 2019;17:219-229.
4. Watson PH, Barnes RO. A proposed schema for classifying human research biobanks. Biopreserv Biobank. 2011;9:327-333.
5. Coppola L, Gianchone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17:172.
6. Worton L, Gali B, Carvalho K, Tarling T, Matzke L, Watson PH. Analysis of trends in biospecimen complexity in cancer research over two decades. Biopreserv Biobank. Published online September 9, 2021. doi:10.1089/bio.2021.0078
7. Shabihkhani M, Lucey GM, Wei B, et al. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem. 2014;47:258-266.
8. Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med. 2014;138:1520-1530.
9. Simeon-Dubach D, Watson P. Biobanking 3.0: evidence based and customer focused biobanking. Clin Biochem. 2014;47:300–308.
10. Cole A, Cheah S, Dee S, Hughes S, Watson PH. Biospecimen use correlates with emerging techniques in cancer research: impact on planning future biobanks. Biopreserv Biobank. 2012;10:518-525.
11. Zhao Y, Mehta M, Walton A, et al. Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas. PLoS One. 2019;14:e0216050.
12. Gaffney EF, Rieggeman, Grizzle WE, Watson PH. Factors that drive the increasing use of FFPE tissue in basic and translational cancer research. Biotech Histochem. 2018;93:373-386.
13. Altekruse SF, Rosenfeld GE, Carrick DM, et al. SEER cancer registry biospecimen research: yesterday and tomorrow. Cancer Epidemiol Biomarkers Prev. 2014;23:2681-2687.
14. Noble DG, Mandt RL, Couce ME, Ayers LW, Parwani AV. Researchers increasingly request custom fresh tissue samples from CHTN MWD over conventionally biobanked frozen and fixed tissues. In: International Society of Biological and Environmental Repositories (ISBER) Virtual Annual Meeting, International Society of Biological and Environmental Repositories (ISBER) Annual Meeting, 2021. Virtual.
15. Mackenzie F. Biobanking trends, challenges, and opportunities. PdF. 2014;81:245-251.
16. National Cancer Institute (NCI). National Cancer Institute – Biorepositories and Biospecimen Research Branch (NCI-BBBR). Accessed January 31, 2022.
17. Grizzle WE, Bledsoe MJ, Al Difalha S, Otulana D, Sexton KC. The utilization of biospecimens: Impact of the choice of biobanking model. Biopreserv Biobank. 2019;17:230-242.
18. Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark. 2010;9:531-549.
19. National Standards and Standard Operating Protocols. Canadian Tissue Repository Network (CTRNet). Accessed January 31, 2022. https://www.ctrnet.ca/en/resources/national-standards/
20. Biospecimen Research Database. National Cancer Institute, Biorepositories & Biospecimen Research Branch; Biospecimen Research - Standard Operating Protocols. Accessed January 31, 2022. https://bed.nci.nih.gov/bed/soop-search
21. Elliott P, Peakman TC, on behalf of UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37:234-241.
22. Snell J, Watson PH, on behalf of UK Biobank. Biobanking trends, challenges, and opportunities. Biopreserv Biobank. 2019,17:219-222.
23. Loken SD, Demetrick DJ. A novel method for freezing and storing research tissue bank specimens. Hum Pathol. 2005;36:977-980.
24. Carrick DM, Black A, Gohagan JK, et al. The PLCO biopreservatory: creating, maintaining, and administering a unique biospecimen resource. Rev Recent Clin Trials. 2015;10(3):212-222.
25. Ekhloud N, Andrianarison NH, Erckert E, et al. Extending the minimum information about biobank data sharing terminology to describe samples, donors and events. Biopreserv Biobank. 2020;18:151-164.
26. Moore HM, Kelly A, Jewell SD, et al. Biospecimen reporting for improved study quality: Biopreserv Biobank. 2011;9:57-70.
27. Lawrence E, Sims J, Gander A, et al. The barriers and motivators to using human tissues for research: the views of UK-based biomedical researchers. Biopreserv Biobank. 2020;18:266-273.
28. Matzke LA, Tarling TE, Gali B, et al. Finding the value in biobanks: enhancing the CTRNet locator. Biopreserv Biobank. Published online July 12, 2021. doi:10.1089/bio.2021.0043
29. Henderson GE, Cadigan RJ, Edwards TP, et al. Characterizing biobank organizations in the U.S. results from a national survey. Genome Med. 2013:5:3.
30. Eiseeman E, Haga SB. Handbook of Human Tissue Sources. A National Resource of Human Tissue Samples. RAND Corp Washington DC Science and Technology Policy Inst; 1999.
31. O’Donoghue S, Dee S, Byrne JA, Watson PH. How Many Health Research Biobanks Are There? Biopreserv Biobank. Published online September 28, 2021. doi:10.1089/bio.2021.0063
32. BBMRI Directory. Biobanking and Biomolecular resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC). Accessed January 31, 2022. https://directory.bbmri-eric.eu/en/menu/main/app-molgenis-app-biobank-explorer/
33. CTRNet Biobank Locator. Canadian Tissue Repository Network (CTRNet). Accessed January 31, 2022. https://biobanking.org/locator
34. NSW Biobank. New South Wales Health Pathology Biobank Locator. Accessed January 31, 2022. https://biobanking.org/locator
35. UKCRC Tissue Directory. UK Clinical Research Collaboration Tissue Directory about. Accessed January 31, 2022. https://biobanking.org/#DirectorySection
36. Dhall A, McDonald TE, Gallagher RP, et al. A Simple Provider Customisation for the British Columbia Genomics’ Project (BCGP). Int J Epidemiol. 2019;48:377–378k.
37. Braun L, Daudt HM, Watson P. Overcoming the translational roadblocks: a cancer care and research model. Clin Transl Med. 2014;3:31.
38. Biobanking and Biospecimen Research Services – Access Biospecimens and Data. BBRS-TRT. Accessed January 31, 2022. https://www.bcrc.ca/services/biobanking-biospecimen-research-services/researchers/access-biospecimens-data
39. Cardiovascular Tissue Registry. HLF CTR. Accessed January 31, 2022. https://www.hlbc.ca/services/cardiovascular-tissue-registry/
40. Lung Tissue Registry. HLI-LTR. Accessed January 31, 2022. https://www.hlbc.ca/services/lung-tissue-registry/
41. Canadian Institutes of Health Research G C. Canadian Institutes of Health Research, Health Services and Policy Research Institute. Canadian Health services and policy research investments. Published November 20, 2008. Accessed January 7, 2022. https://cihr-irsc.gc.ca/map-carte_ihspr-isps/e/ca.html
42. Hughes SE, Barnes RO, Watson PH. Biospecimen use in cancer research over two decades. Biopreserv Biobank. 2010;8:89-97
43. Braun L, Lesperance M, Mes-Massons AM, Tao MS, Watson PH. Individual investigator profiles of biospecimen use in cancer research. Biopreserv Biobank. 2014;12:192-198.
44. Castillo-Pelayo T, Babinszky S, LeBlanc J, Watson PH. The importance of biobanking in cancer research. Biopreserv Biobank. 2015;13:172-177.
45. Holub P, Swertz M, Reul H, van Enckevort D, Müller H, Litton JE. BBMRI-ERIC directory: 515 biobanks with over 60 million biological samples. Biopreserv Biobank. 2016;14(6):559-562. doi:10.1089/bio.2016.0088
54. Tarling T, Matzke LAM, Rush A, Gali B, Byrne JA, Watson PH. Vignettes to illustrate the value of tumor biobanks in cancer research in Canada. Biopreserv Biobank. Published online June 24, 2021. doi:10.1089/bio.2021.0002

55. Kaplan-Meier Plotter. KM Plotter. Accessed January 31, 2022. https://kmplot.com/analysis/

56. National Cancer Institute Cancer Imaging Program. Cancer Imaging Archive. Accessed January 31, 2022. https://www.cancerimagingarchive.net/

57. Doucet M, Yuille M, Georghiou L, Dagher G. Biobank sustainability: current status and future prospects. J Biorepository Sci Appl Med. Published online 2017. doi:10.2147/bsam.s100899

58. Watson PH, Nussbeck SY, Carter C, et al. A Model to estimate frozen tissue collection targets in biobanks to support cancer research. Biopreserv Biobank. 2015;13(5):356-362.

59. Scudellari M. Biobank managers bemoan underuse of collected samples. Nat Med. 2013;19(3):253-253.

60. Allocca CM, Bledsoe MJ, Albert M, et al. Biobanking in the COVID-19 era: learnings and field expectations during cycles of promise and disappointment. New Genet Soc. 2015;34:417-436.

61. Byrne JA, Carpenter JE, Carter C, et al. Building research support capacity across human health biobanks during the COVID-19 Pandemic. Biomark Insights. 2021;16:11772719211024100.

62. Hofman P, Puchois P, Brest P, Lahou H, Simeon-Dubach D. Possible consequences of the COVID-19 pandemic on the use of biospecimens from cancer biobanks for research in academia and biopharma. Nat Med. 2020;26:809-810.

63. Mulholland EJ. Impact of COVID-19 on in vivo work and patient sample availability for cancer research. Nat Rev Cancer. 2021;21:139-140.

64. Unger JM, Xiao H, LeBlanc M, Hershman DL, Blanke CD. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Netw Open. 2021;4:e2118433.

65. Watson PH. Biospecimen complexity - the next challenge for cancer research biobanks? Clin Cancer Res. 2017;23:894-898.

66. Hartman V, Matzke L, Watson PH. Biospecimen complexity and the evolution of biobanks. Biopreserv Biobank. 2019;17:264-270.

67. Matzke LAM, Fombonne B, Watson PH, Moore HM. Fundamental considerations for biobank legacy planning. Biopreserv Biobank. 2016;14:99-106.

68. Cadiogan RJ, Edwards TP, Lassiter D, Davis AM, Henderson GE. “Forward-Thinking” in U.S. Biobanking. Genet Test Mol Biomarkers. 2017;21:148-154.

69. Shea KE, Wagner EL, Marchesani L, Meagher K, Giffen C. Efficiently maintaining a national resource of historical and contemporary biological collections: the NHLBI biorepository model. Biopreserv Biobank. 2017;15:17-19.

70. Allen SC, Dixon MD, Switchenks JM, Penta RD. Cancer donor preferences for disposition of their biospecimens after biobank closure. Cancer. 2017;123:4648-4652.

71. Aarden E. Projecting and producing ‘usefulness’ of biomedical research infrastructures: or why the Singapore Tissue Network closed. SciPublic Policy. 2017;44:753-762.

72. Stephens N, Dimond R. Closure of a human tissue biobank: individual, institutional, and field expectations during cycles of promise and disappointment. New Genet Soc. 2015;34:417-436.

73. Radvanyi L. Ontario tumour bank to cease operations in 2022-23. Ontario Institute for Cancer Research (OICR). Accessed January 5, 2022. https://oicr.on.ca/programs/ontario-tumour-bank/

74. Harris AJ. COVID-19 and cancer research. Br J Cancer. 2020;123:689-690.

75. Grizzle WE, Sexton KC. Commentary on improving biospecimens utilization by classic biobanks: identifying past and minimizing future mistakes. Biopreserv Biobank. 2019;17:243-247.

76. Grizzle WE, Sexton KC, McGarvey D, Menchhofen ZV, LiVolsi V. Lessons learned during three decades of operations of two prospective biorepositories. Biopreserv Biobank. 2018;16:483-492.